(Reuters) – Leading U.S. drugmaker Pfizer Inc racked up its biggest miss on sales in a year in the first quarter, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz.
Source:: Reuters – Business News
